Alterity is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Alterity generates no commercial product revenue and focuses entirely on research and development. Its lead and only active clinical asset is ATH434, an oral small-molecule drug candidate targeting Multiple System Atrophy, a rare and progressive neurodegenerative disorder. ATH434 works as an iron chaperone, binding and redistributing excess reactive iron in the central nervous system to reduce the aggregation of α-synuclein proteins. ATH434 has completed Phase 2 clinical development and is Phase 3-ready, holding Orphan Drug and Fast Track designations from the FDA. Beyond Multiple System Atrophy, Alterity evaluates ATH434 in preclinical studies for Parkinson's disease and Friedreich's Ataxia. Alterity's business model centers on advancing drug candidates through clinical trials to either commercialize them directly or license them to larger pharmaceutical companies. Alterity maintains a lean operational structure by leasing laboratory space rather than owning facilities, funding operations through equity offerings and research grants.